A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients

The aim of this study was to evaluate the cost-effectiveness of Anbainuo (ABN) plus methotrexate (MTX) (ABN+MTX) versus conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients. Forty-eight moderate to severe RA patients underwent ABN+MTX or cDMARDs treatment were consecutively enrolled and assigned to ABN+MTX group (n = 26) and control group (n = 22). Patients were followed up and their disease activity and quality of life (QoL) were evaluated at 3rd month, 6th month and 12th month after initiation of treatment. Treatment costs of 2 groups were calculated, then pharmacoeconomic analysis was performed. ABN+MTX increased drug cost and total cost while decreased indirect cost compared with cDMARDs after 12-month treatment. ABN+MTX group gained additional 0.22 quality-adjusted life years (QALY) and yielded an incremental cost-effectiveness ratio (ICER) of (sic)104,293.6 per QALY after treatment. Sensitivity analysis reveals that rising ABN price by 20% produced an ICER of (sic)130,403.6 per QALY, which was still lower than 3 times of the mean gross domestic product (GDP) per capita during the same period in China ((sic)165,960). Besides, ABN+MTX was more cost-effective in severe RA patients compared to moderate RA patients. ABN+MTX is cost-effective in treating moderate to severe RA patients compared with cDMARDs, although the total cost of ABN+MTX is relatively higher.